REAfinity Recombinant Antibodies are generated through advanced antibody design, genetic engineering, and screening technologies. These technologies combine genetic material from immunized animals with display-based selection from in-house antibody libraries.
The antigen-binding region of a mouse IgG derived from a hybridoma is fused with a human IgG1 Fc region. The Fc region is mutated to prevent binding to Fcγ receptors. A single, standardized mammalian cell line expresses this chimeric construct, ensuring consistent batch quality across all REAfinity Recombinant Antibodies.
After successful development in R&D, each antibody candidate is transferred to our in-house recombinant and monoclonal antibody production facility for large-scale manufacturing, continuous monitoring, and long-term consistency assurance.
Thanks to our advanced recombinant antibody engineering and production system, all antibodies are free of light-chain, cell-, and serum-derived contaminants. By choosing REAfinity Recombinant Antibodies, you invest in reliability from the start – eliminating the need for re-validation and saving valuable research time.